Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant

NCT00639717 | Completed Phase 2 Results DMC

• 1 other identifier: umcc 2008.003
• Study Type: interventional
• Target: 48
• Locations: 1 country
• Sites: 1

Brief Summary

This research study investigates the benefits and possible risks of adding both etanercept (Enbrel) and ECP (extracorporeal photopheresis) to the conventional preventative (or prophylactic) treatments for graft-versus-host disease (GVHD). GVHD is a common, serious, and too often fatal, complication after matched unrelated donor stem cell transplantation, regardless of the pre-transplant conditioning regimen used (full or reduced intensity). Reduced intensity transplants which employ lower doses of chemotherapy during the conditioning phase of the transplant, are less toxic than full intensity transplants. Reduced intensity transplants may extend the unrelated donor transplant option to older patients or to patients with existing medical conditions or illness, where a full intensity transplant is not possible. To be successful, reduced intensity transplants need to offset any lower effectiveness in killing cancer cells during the conditioning phase, with the establishment of a donor cell, graft-versus-leukemia effect (GVL). The GVL effect and GVHD are associated with each other and therefore, the goal of GVHD prophylaxis for this study is not so much to prevent all GVHD, but rather to prevent serious and fatal acute GVHD. Most GVHD-related deaths are either the direct consequence of severe GVHD or from infections associated with intense immunosuppression, a consequence of the standard treatments for acute GVHD, which almost always include high-dose steroids. A more effective prophylaxis therapy that allows for the GVL effect to develop, while limiting the exposure to high-dose steroids may reduce transplant mortality and morbidity. We also will study how key chemical and cellular factors relate to clinical outcome.

Conditions

Graft Versus Host Disease

Keywords

GVHD

Outcome Measures

Primary Outcomes (2)

• Percentage of Patients Alive at 6 Months

  Overall survival at 6 months

  6 months

• Percentage of Patients Who Experienced Relapse by 6 Months

  Relapse rate at 6 months. Relapse is defined as recurrence of disease.

  6 months

Secondary Outcomes (3)

• The Percentage of Patients That Experienced Graft Versus Host Disease

  6 Months

• Measured Level of Circulating Plasma Markers After Transplant

  100 days

• Regulatory T Cell Numbers Post-transplant

  180 days

Study Arms (1)

Etanercept and ECP

EXPERIMENTAL

Etanercept and ECP (Extracorporeal Photopheresis) in addition to standard GVHD prevention: Etanercept will be given twice weekly by subcutaneous injection starting on the day of HSCT (Hematopoietic stem cell transplantation) conditioning until 8 weeks post transplant. ECP treatments will begin at once weekly starting at 4 weeks post transplant and continue at less frequent intervals until 6 months post transplant. GVHD prophylaxis will consist of a standard two drug regimen: mycophenolate for 4 weeks and tacrolimus (titrated to a therapeutic level) for 8 weeks, then weaned over 4 months with discontinuation by 6 months post-transplant.

Procedure: stem cell transplant; Drug: tacrolimus (standard GVHD prophylaxis); Drug: mycophenolate (standard GVHD prophylaxis); Drug: etanercept; Drug: methoxsalen

Interventions

stem cell transplant PROCEDURE

reduced intensity, matched unrelated donor stem cell transplant

Etanercept and ECP

tacrolimus (standard GVHD prophylaxis) DRUG

Tacrolimus(or cyclosporine when necessary) Tacrolimus will begin on day -3, IV or oral. Target trough level for tacrolimus is 8-12 ng/ml. In the absence of GVHD, tacrolimus tapering will begin on day +56 post transplant

Etanercept and ECP

mycophenolate (standard GVHD prophylaxis) DRUG

Mycophenolate will begin on day 0 at 10 mg/kg/dose (up to 1 gram per dose) every 8 hours orally or intravenously and will continue until day 28.

Etanercept and ECP

etanercept DRUG

Etanercept will be given at a dose 0.4 mg/kg (actual weight) up to a maximum dose of 25 mg, subcutaneously, twice weekly from day 0 to day 56 (16 doses)

Also known as: Enbrel

Etanercept and ECP

methoxsalen DRUG

Methoxsalen (UVADEX) treatments by Extracorporeal photopheresis (ECP) will be started day +28 post transplant and given weekly. On day +70 post transplant ECP frequency will be given every other week. On day +100 post transplant ECP will be given monthly until day +180 and stopped.

Also known as: UVADEX

Etanercept and ECP

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Candidate for unrelated donor (allogeneic) HSCT for hematologic conditions, either malignant or non-malignant.
• Donor can be unrelated marrow, blood or cord blood.
• Any disease for which unrelated donor transplant is appropriate is eligible except:
• Progressive or poorly controlled malignancies for which the likelihood of durable disease control \[i.e., patients expected to have at least 6 months PFS from date of transplant\] is \<25%.
• This determination of likelihood of durable disease control must take into account the patient's disease status and consideration of the agents and doses used in the reduced intensity conditioning regimen.
• The determination of adequate disease control will be certified by the PI or designee on the eligibility checklist.
• Patients may be consented to this trial based on disease control at the time of consent, but later removed from the trial prior to initiation of transplant conditioning regimen if disease status confirmation between consenting and transplant changes. In the event this occurs these patients will be replaced.
• Must be receiving a recognized reduced intensity transplant as determined by the University of Michigan Blood and Marrow Transplantation Program.
• Patients age 50 or older are eligible based on age.
• Patients may be \<50 years old if they are eligible for a reduced intensity conditioning regimen based on disease type (eg, indolent lymphoma) or if comorbidities preclude a full-intensity transplant.
• Patients must have adequate venous access by either peripheral vein or central line so that ECP can be performed.
• Patients must be expected to tolerate the fluid shifts associated with ECP. The primary reason for expected intolerance of ECP is small size (ie, \<30kg weight), but other factors may also be considered in this determination.

You may not qualify if:

• Not a candidate for a reduced intensity transplant conditioning regimen (based on the current U-M BMT program clinical guidelines).
• Patient has a suitable related donor available for transplant.
• Karnofsky or Lansky performance status of \< 50% at the time of admission for HSCT
• Patients with evidence of HIV infection or other opportunistic infection including but not limited to Tuberculosis and Histoplasmosis.
• Patients with active bacterial, fungal or viral infection not responding to treatment.
• Any medical or psychological conditions that would keep the patient from complying with the protocol and/or would markedly increase the morbidity and mortality from the procedure.
• Pregnancy.
• T-cell depleted allograft

Sponsors & Collaborators

• University of Michigan Rogel Cancer Center: lead
• Mallinckrodt: collaborator
• Amgen: collaborator

Study Sites (1)

University of Michigan Cancer Center

Ann Arbor, Michigan, 48109, United States

Location

MeSH Terms

Conditions

Graft vs Host Disease

Interventions

Stem Cell Transplantation; Tacrolimus; Mycophenolic Acid; Etanercept; Methoxsalen

Condition Hierarchy (Ancestors)

Immune System Diseases

Intervention Hierarchy (Ancestors)

Cell Transplantation; Cell- and Tissue-Based Therapy; Biological Therapy; Therapeutics; Transplantation; Surgical Procedures, Operative; Macrolides; Lactones; Organic Chemicals; Caproates; Acids, Acyclic; Carboxylic Acids; Fatty Acids; Lipids; Immunoglobulin Fc Fragments; Immunoglobulin Fragments; Peptide Fragments; Peptides; Amino Acids, Peptides, and Proteins; Immunoglobulin Constant Regions; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Serum Globulins; Globulins; Receptors, Tumor Necrosis Factor; Receptors, Cytokine; Receptors, Immunologic; Receptors, Cell Surface; Membrane Proteins; Furocoumarins; Coumarins; Benzopyrans; Pyrans; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds, 3-Ring

Results Point of Contact

• Title: Dr. Gregory Yanik
• Organization: University of Michigan Comprehensive Cancer Center

jelevine@umich.edu

734-764-3243

Study Officials

• Gregory Yanik, MD

  University of Michigan Rogel Cancer Center

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 11, 2008
• First Posted: March 20, 2008
• Study Start: March 1, 2009
• Primary Completion: January 1, 2012
• Study Completion: April 1, 2016
• Last Updated: August 1, 2017
• Results First Posted: September 25, 2014

Record last verified: 2017-07

Locations

US (1)